We conducted a single arm trial of low dose rapamycin (1 mg/day for 4 weeks) in cognitively normal adults aged 45 to 65 years, prior to detectable AD pathology, stratified by APOE genotype. The primary outcome was cerebral blood flow (CBF), while secondary outcomes included plasma metabolomics, inflammatory cytokines, AD biomarkers, and gut microbiome composition.

Twenty-three participants completed the study, including nine APOE4 carriers and fourteen non-carriers. Rapamycin significantly increased CBF in APOE4 carriers, with increases exceeding 15% across multiple brain regions, and improved metabolic and inflammatory profiles with minimal adverse effects. In contrast, non-carriers showed no significant change in CBF and exhibited distinct physiological responses, highlighting genotype dependent effects.

These findings suggest that rapamycin may mitigate early cerebrovascular and systemic dysfunction in APOE4 carriers and support a precision medicine approach in which therapeutic response is influenced by genotype.

Includes 8 critical CVSS score fixes.

The molecular structure of the drug, called rentosertib, was generated with the assistance of A.I. Results of the new study, published Monday in the journal Nature Biotechnology, show that the drug reduced the biological markers of age as measured by six “aging clocks,” a different kind of A.I. technology designed to predict a person’s morbidity and mortality.

This report investigates the potential interplay between UroA and the AMPK/SIRT/mTOR signaling pathway, elucidating a plausible mechanism through which UroA regulates the autophagic-lysosomal system and mitigates neuroinflammation via modulation of this axis.

Very interesting study showing benefits for adult autism, albeit with short duration. Study Summary:

• To the pregnant moms: The researchers injected a bacterial compound (lipopolysaccharide) to induce mild maternal inflammation. They did not give rapamycin to the pregnant mice.
• To the offspring in adulthood: Once the offspring grew into early or older adulthood and displayed autism-like traits, researchers administered rapamycin to them - either as a single injection or through daily injections - to observe its immediate functional effects on the adult brain.

The researchers found several key outcomes after administering rapamycin to adult mice exposed to maternal inflammation:

• Rapid Reduction of Repetitive Behaviors: A single low dose rapidly reversed repetitive behaviors (such as excessive grooming and circling) back to normal levels within just 2 hours.
• Normalization of Sensory Sensitivity: The treatment restored normal tactile tolerance in the mice, allowing them to explore rough surfaces they had previously avoided due to sensory over-responsivity.
• Calmed Neural Excitability: Rapamycin reduced brain cell hyper-excitability in the sensory cortex, lowered seizure severity, and restored functional connectivity across brain networks to match normal control mice.
• Shift in Gene Expression: The acute treatment quickly shifted the expression of genes tied to cell excitability and autism risk back toward typical baseline levels.

Key Limitations Noted by the Researchers

• Temporary Effects: The benefits of a single dose were short-lived, with repetitive behaviors returning to elevated levels after 72 hours.

Summary

• In mice exposed to inflammation during pregnancy, the offspring developed lasting autism-like brain and behavior changes, suggesting that early inflammation can disrupt brain development in ways that persist into adulthood.
• A single dose of rapamycin rapidly improved several of those changes, including brain overactivity, seizure risk, sensory sensitivity, repetitive behaviors and abnormal brain functional network organization.
• The findings suggest that some autism-related brain changes may still be treatable in adulthood, pointing to possible therapeutic approaches that target the underlying pathway rather than only symptoms.
• The effects of rapamycin are temporary, and repeated dosing loses efficacy, making rapamycin, itself, an unlikely candidate as a broadly-used treatment.

"Mechanistically, [SGLT2 inhibitors] induce metabolic adaptations that resemble caloric restriction and ketogenic states, attenuate systemic inflammation, improve mitochondrial function, and enhance cellular resilience against the burden of senescence.

"Supporting this concept, multiple preclinical studies have shown that SGLT2 inhibitors extend lifespan and ameliorate age-related functional decline in animal models.

"Notably, recent findings indicate that SGLT2 inhibitors can reduce senescent cell burden and modulate the senescence-associated secretory phenotype, raising the possibility that they possess senotherapeutic—or even senolytic—properties targeting a fundamental driver of aging. Collectively, these data suggest that SGLT2 inhibitors may influence core aging pathways beyond their glucose-lowering and cardiorenal protective effects."